<DOC>
	<DOCNO>NCT01700621</DOCNO>
	<brief_summary>The investigator aim establish non-inferiority concomitant administration measles-rubella rotavirus vaccine measles-rubella vaccine give alone term measles seroconversion rate . The primary study hypothesis measles seroconversion rate define percentage child seroconverting measles measles serum antibody concentration &gt; =1:120 8 week post vaccination concomitant administration measles-rubella rotavirus vaccine non-inferior obtained measles-rubella vaccine give alone child 9 month age receive primary rotavirus vaccine series first dose 6 10 week second least 4 week later seronegative measles antibody pre-vaccination sample .</brief_summary>
	<brief_title>Coadministration Measles-rubella Rotavirus Vaccines</brief_title>
	<detailed_description />
	<mesh_term>Measles</mesh_term>
	<mesh_term>Rubella</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Child 9 month age eligible measlesrubella vaccination document evidence primary rotavirus vaccine series first dose 6 10 week age second dose least 4 week first dose healthy infant free chronic serious medical condition determine history physical examination time study enrollment parents/guardians participant able understand follow study procedure agree participate study provide sign informed consent hypersensitivity component measlesrubella Rotarix vaccine would preclude administration vaccine history intussusception , intestinal malformation , abdominal surgery know history measles and/or rubella disease history previous receipt measles and/or rubella vaccine use immunosuppressive drug immunoglobulin and/or blood product since birth anticipate study period current enrolment intervention trial use investigational drug vaccine throughout study period participant report plan leave teh study area completion study</criteria>
	<gender>All</gender>
	<minimum_age>9 Months</minimum_age>
	<maximum_age>11 Months</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>rotavirus</keyword>
</DOC>